Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Lack of a significant legacy effect of baseline blood pressure 'treatment naivety' on all-cause and cardiovascular mortality in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

Ho CLB, Breslin M, Chowdhury EK, Doust J, Reid CM, Davis BR, Simpson LM, Nelson MR.

J Hypertens. 2019 Oct 3. doi: 10.1097/HJH.0000000000002280. [Epub ahead of print]

PMID:
31584517
2.

Effects of Antihypertensive Class on Falls, Syncope, and Orthostatic Hypotension in Older Adults: The ALLHAT Trial.

Juraschek SP, Simpson LM, Davis BR, Beach JL, Ishak A, Mukamal KJ.

Hypertension. 2019 Oct;74(4):1033-1040. doi: 10.1161/HYPERTENSIONAHA.119.13445. Epub 2019 Sep 3.

PMID:
31476905
3.

Biosensors to Monitor Water Quality Utilizing Insect Odorant-Binding Proteins as Detector Elements.

Dimitratos SD, Hommel AS, Konrad KD, Simpson LM, Wu-Woods JJ, Woods DF.

Biosensors (Basel). 2019 May 14;9(2). pii: E62. doi: 10.3390/bios9020062.

4.

Sustained blood pressure control and coronary heart disease, stroke, heart failure, and mortality: An observational analysis of ALLHAT.

Bowling CB, Davis BR, Luciano A, Simpson LM, Sloane R, Pieper CF, Einhorn PT, Oparil S, Muntner P.

J Clin Hypertens (Greenwich). 2019 Apr;21(4):451-459. doi: 10.1111/jch.13515. Epub 2019 Mar 13.

5.

Risk Factors Influencing Outcomes of Atrial Fibrillation in ALLHAT.

Haywood LJ, Davis BR, Piller LB, Simpson LM, Ghosh A, Einhorn PT, Ford CE, Probstfield JL, Soliman EZ, Wright JT Jr; ALLHAT Collaborative Research Group.

J Natl Med Assoc. 2018 Aug;110(4):343-351. doi: 10.1016/j.jnma.2017.07.003. Epub 2017 Jul 24.

6.

Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).

Dewland TA, Soliman EZ, Yamal JM, Davis BR, Alonso A, Albert CM, Simpson LM, Haywood LJ, Marcus GM.

Circ Arrhythm Electrophysiol. 2017 Dec;10(12). pii: e005463. doi: 10.1161/CIRCEP.117.005463.

7.

Influence of Prevalent and Incident Atrial Fibrillation on Post-Trial Major Events in ALLHAT.

Haywood LJ, Davis BR, Piller LB, Cushman WC, Cutler JA, Ford CE, Simpson LM, Ghosh A, Soliman EZ, Wright JT Jr; ALLHAT Collaborative Research Group.

J Natl Med Assoc. 2017 Autumn;109(3):172-181. doi: 10.1016/j.jnma.2017.02.005. Epub 2017 Mar 18.

8.

Kidney function of transfused children with sickle cell anemia: Baseline data from the TWiTCH study with comparison to non-transfused cohorts.

Alvarez O, Nottage K, Simpson LM, Wood J, Davis BR, Fuh B, Sarnaik S, Aygun B, Helton K, Ware RE.

Am J Hematol. 2017 Nov;92(11):E637-E639. doi: 10.1002/ajh.24871. Epub 2017 Aug 17. No abstract available.

9.

Electrocardiographic Left Ventricular Hypertrophy Predicts Cardiovascular Morbidity and Mortality in Hypertensive Patients: The ALLHAT Study.

Bang CN, Soliman EZ, Simpson LM, Davis BR, Devereux RB, Okin PM; ALLHAT Collaborative Research Group.

Am J Hypertens. 2017 Sep 1;30(9):914-922. doi: 10.1093/ajh/hpx067.

10.

Association between chronic kidney disease and cancer mortality: A report from the ALLHAT.

Chen DP, Davis BR, Simpson LM, Cushman WC, Cutler JA, Dobre M, Ford CE, Louis GT, Muntner P, Oparil S, Piller LB, Pressel SL, Sarnak MJ, Whelton PK, Wright JT, Rahman M.

Clin Nephrol. 2017 Jan;87 (2017)(1):11-20.

PMID:
27900942
11.

The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

Kronish IM, Lynch AI, Oparil S, Whittle J, Davis BR, Simpson LM, Krousel-Wood M, Cushman WC, Chang TI, Muntner P.

Hypertension. 2016 Jul;68(1):39-45. doi: 10.1161/HYPERTENSIONAHA.115.06960. Epub 2016 May 23.

12.

Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.

Chen G, McQuade JL, Panka DJ, Hudgens CW, Amin-Mansour A, Mu XJ, Bahl S, Jané-Valbuena J, Wani KM, Reuben A, Creasy CA, Jiang H, Cooper ZA, Roszik J, Bassett RL Jr, Joon AY, Simpson LM, Mouton RD, Glitza IC, Patel SP, Hwu WJ, Amaria RN, Diab A, Hwu P, Lazar AJ, Wargo JA, Garraway LA, Tetzlaff MT, Sullivan RJ, Kim KB, Davies MA.

JAMA Oncol. 2016 Aug 1;2(8):1056-64. doi: 10.1001/jamaoncol.2016.0509.

13.

Visit-to-Visit Variability of BP and CKD Outcomes: Results from the ALLHAT.

Whittle J, Lynch AI, Tanner RM, Simpson LM, Davis BR, Rahman M, Whelton PK, Oparil S, Muntner P.

Clin J Am Soc Nephrol. 2016 Mar 7;11(3):471-80. doi: 10.2215/CJN.04660415. Epub 2016 Feb 18.

14.

Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study.

Muntner P, Whittle J, Lynch AI, Colantonio LD, Simpson LM, Einhorn PT, Levitan EB, Whelton PK, Cushman WC, Louis GT, Davis BR, Oparil S.

Ann Intern Med. 2015 Sep 1;163(5):329-38. doi: 10.7326/M14-2803.

15.

The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials.

Preiss D, Campbell RT, Murray HM, Ford I, Packard CJ, Sattar N, Rahimi K, Colhoun HM, Waters DD, LaRosa JC, Amarenco P, Pedersen TR, Tikkanen MJ, Koren MJ, Poulter NR, Sever PS, Ridker PM, MacFadyen JG, Solomon SD, Davis BR, Simpson LM, Nakamura H, Mizuno K, Marfisi RM, Marchioli R, Tognoni G, Athyros VG, Ray KK, Gotto AM, Clearfield MB, Downs JR, McMurray JJ.

Eur Heart J. 2015 Jun 21;36(24):1536-46. doi: 10.1093/eurheartj/ehv072. Epub 2015 Mar 23. Review.

16.

Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT.

Piller LB, Simpson LM, Baraniuk S, Habib GB, Rahman M, Basile JN, Dart RA, Ellsworth AJ, Fendley H, Probstfield JL, Whelton PK, Davis BR; ALLHAT Collaborative Research Group.

J Gen Intern Med. 2014 Nov;29(11):1475-83. doi: 10.1007/s11606-014-2947-1.

17.

Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

Muntner P, Levitan EB, Lynch AI, Simpson LM, Whittle J, Davis BR, Kostis JB, Whelton PK, Oparil S.

J Clin Hypertens (Greenwich). 2014 May;16(5):323-30. doi: 10.1111/jch.12290. Epub 2014 Apr 16.

18.

Glycated hemoglobin measurement and prediction of cardiovascular disease.

Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, Khan H, Butterworth AS, Wormser D, Kaptoge S, Kondapally Seshasai SR, Thompson A, Sarwar N, Willeit P, Ridker PM, Barr EL, Khaw KT, Psaty BM, Brenner H, Balkau B, Dekker JM, Lawlor DA, Daimon M, Willeit J, Njølstad I, Nissinen A, Brunner EJ, Kuller LH, Price JF, Sundström J, Knuiman MW, Feskens EJ, Verschuren WM, Wald N, Bakker SJ, Whincup PH, Ford I, Goldbourt U, Gómez-de-la-Cámara A, Gallacher J, Simons LA, Rosengren A, Sutherland SE, Björkelund C, Blazer DG, Wassertheil-Smoller S, Onat A, Marín Ibañez A, Casiglia E, Jukema JW, Simpson LM, Giampaoli S, Nordestgaard BG, Selmer R, Wennberg P, Kauhanen J, Salonen JT, Dankner R, Barrett-Connor E, Kavousi M, Gudnason V, Evans D, Wallace RB, Cushman M, D'Agostino RB Sr, Umans JG, Kiyohara Y, Nakagawa H, Sato S, Gillum RF, Folsom AR, van der Schouw YT, Moons KG, Griffin SJ, Sattar N, Wareham NJ, Selvin E, Thompson SG, Danesh J.

JAMA. 2014 Mar 26;311(12):1225-33. doi: 10.1001/jama.2014.1873.

19.

Author response to lipid-lowering in African Americans in ALLHAT-optimism bias?

Margolis KL, Davis BR, Baimbridge C, Ciocon JO, Cuyjet AB, Dart RA, Einhorn PT, Ford CE, Gordon D, Hartney TJ, Julian Haywood L, Holtzman J, Mathis DE, Oparil S, Probstfield JL, Simpson LM, Stokes JD, Wiegmann TB, Williamson JD.

J Clin Hypertens (Greenwich). 2013 Dec;15(12):941. doi: 10.1111/jch.12220. Epub 2013 Oct 30. No abstract available.

20.

The burden and correlates of hypertension in rural Ghana: a cross-sectional study.

Williams EA, Keenan KE, Ansong D, Simpson LM, Boakye I, Boaheng JM, Awuah D, Nkyi CA, Nyannor I, Arhin B, Alder S, Benson LS, Dickerson TT.

Diabetes Metab Syndr. 2013 Jul-Sep;7(3):123-8. doi: 10.1016/j.dsx.2013.06.015. Epub 2013 Jul 30.

PMID:
23953175
21.

Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

Margolis KL, Davis BR, Baimbridge C, Ciocon JO, Cuyjet AB, Dart RA, Einhorn PT, Ford CE, Gordon D, Hartney TJ, Julian Haywood L, Holtzman J, Mathis DE, Oparil S, Probstfield JL, Simpson LM, Stokes JD, Wiegmann TB, Williamson JD; ALLHAT Collaborative Research Group.

J Clin Hypertens (Greenwich). 2013 Aug;15(8):542-54. doi: 10.1111/jch.12139. Epub 2013 Jun 10.

22.

Identifying subset errors in multiple sequence alignments.

Roy A, Taddese B, Vohra S, Thimmaraju PK, Illingworth CJ, Simpson LM, Mukherjee K, Reynolds CA, Chintapalli SV.

J Biomol Struct Dyn. 2014;32(3):364-71. doi: 10.1080/07391102.2013.770371. Epub 2013 Mar 25.

PMID:
23527867
23.

Modeling active GPCR conformations.

Taddese B, Simpson LM, Wall ID, Blaney FE, Reynolds CA.

Methods Enzymol. 2013;522:21-35. doi: 10.1016/B978-0-12-407865-9.00002-9.

PMID:
23374178
24.

Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial.

Traverse JH, Henry TD, Pepine CJ, Willerson JT, Zhao DX, Ellis SG, Forder JR, Anderson RD, Hatzopoulos AK, Penn MS, Perin EC, Chambers J, Baran KW, Raveendran G, Lambert C, Lerman A, Simon DI, Vaughan DE, Lai D, Gee AP, Taylor DA, Cogle CR, Thomas JD, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Kappenman C, Westbrook L, Piller LB, Simpson LM, Baraniuk S, Loghin C, Aguilar D, Richman S, Zierold C, Spoon DB, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN).

JAMA. 2012 Dec 12;308(22):2380-9. Erratum in: JAMA. 2013 Jan 23;309(4):343. Erratum in: JAMA. 2015 Jul 7;314(1):86.

25.

Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial.

Perin EC, Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DX, Silva GV, Lai D, Thomas JD, Kronenberg MW, Martin AD, Anderson RD, Traverse JH, Penn MS, Anwaruddin S, Hatzopoulos AK, Gee AP, Taylor DA, Cogle CR, Smith D, Westbrook L, Chen J, Handberg E, Olson RE, Geither C, Bowman S, Francescon J, Baraniuk S, Piller LB, Simpson LM, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN).

JAMA. 2012 Apr 25;307(16):1717-26. doi: 10.1001/jama.2012.418. Epub 2012 Mar 24. Erratum in: JAMA. 2015 Jul 7;314(1):86.

26.

G-protein-coupled receptor dynamics: dimerization and activation models compared with experiment.

Taddese B, Simpson LM, Wall ID, Blaney FE, Kidley NJ, Clark HS, Smith RE, Upton GJ, Gouldson PR, Psaroudakis G, Bywater RP, Reynolds CA.

Biochem Soc Trans. 2012 Apr;40(2):394-9. doi: 10.1042/BST20110755. Review.

PMID:
22435818
27.

Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

Cushman WC, Davis BR, Pressel SL, Cutler JA, Einhorn PT, Ford CE, Oparil S, Probstfield JL, Whelton PK, Wright JT Jr, Alderman MH, Basile JN, Black HR, Grimm RH Jr, Hamilton BP, Haywood LJ, Ong ST, Piller LB, Simpson LM, Stanford C, Weiss RJ; ALLHAT Collaborative Research Group.

J Clin Hypertens (Greenwich). 2012 Jan;14(1):20-31. doi: 10.1111/j.1751-7176.2011.00568.x. Epub 2011 Dec 9.

28.

Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial.

Traverse JH, Henry TD, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Forder JR, Byrne BJ, Hatzopoulos AK, Penn MS, Perin EC, Baran KW, Chambers J, Lambert C, Raveendran G, Simon DI, Vaughan DE, Simpson LM, Gee AP, Taylor DA, Cogle CR, Thomas JD, Silva GV, Jorgenson BC, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Smith DX, Baraniuk S, Piller LB, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD; Cardiovascular Cell Therapy ResearchNetwork.

JAMA. 2011 Nov 16;306(19):2110-9. doi: 10.1001/jama.2011.1670. Epub 2011 Nov 14.

29.

Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).

Piller LB, Baraniuk S, Simpson LM, Cushman WC, Massie BM, Einhorn PT, Oparil S, Ford CE, Graumlich JF, Dart RA, Parish DC, Retta TM, Cuyjet AB, Jafri SZ, Furberg CD, Saklayen MG, Thadani U, Probstfield JL, Davis BR; ALLHAT Collaborative Research Group.

Circulation. 2011 Oct 25;124(17):1811-8. doi: 10.1161/CIRCULATIONAHA.110.012575. Epub 2011 Oct 3.

30.

Modeling GPCR active state conformations: the β(2)-adrenergic receptor.

Simpson LM, Wall ID, Blaney FE, Reynolds CA.

Proteins. 2011 May;79(5):1441-57. doi: 10.1002/prot.22974. Epub 2011 Feb 18.

PMID:
21337626
31.

LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.

Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Simpson LM, Penn MS, Byrne BJ, Perin EC, Gee AP, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Baraniuk S, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moyè LA, Simari RD; Cardiovascular Cell Therapy Research Network.

Tex Heart Inst J. 2010;37(4):412-20.

32.

Bioinformatics and molecular modelling approaches to GPCR oligomerization.

Simpson LM, Taddese B, Wall ID, Reynolds CA.

Curr Opin Pharmacol. 2010 Feb;10(1):30-7. doi: 10.1016/j.coph.2009.11.001. Epub 2009 Dec 16. Review.

PMID:
20015686
33.

Coronary heart disease in moderately hypercholesterolemic, hypertensive black and non-black patients randomized to pravastatin versus usual care: the antihypertensive and lipid lowering to prevent heart attack trial (ALLHAT-LLT).

Margolis KL, Dunn K, Simpson LM, Ford CE, Williamson JD, Gordon DJ, Einhorn PT, Probstfield JL; ALLHAT Collaborative Research Group.

Am Heart J. 2009 Dec;158(6):948-55. doi: 10.1016/j.ahj.2009.10.001.

34.

Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.

Davis BR, Kostis JB, Simpson LM, Black HR, Cushman WC, Einhorn PT, Farber MA, Ford CE, Levy D, Massie BM, Nawaz S; ALLHAT Collaborative Research Group.

Circulation. 2008 Nov 25;118(22):2259-67. doi: 10.1161/CIRCULATIONAHA.107.762229. Epub 2008 Nov 10.

35.

Getting ready to get out: how EMS providers & hospital staff can work together to successfully relocate patients.

Goss JF, Ngo EB, Simpson LM.

JEMS. 2008 May;33(5):72-81. doi: 10.1016/S0197-2510(08)70192-X. No abstract available.

PMID:
18482653
36.

The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosis.

Einhorn PT, Davis BR, Massie BM, Cushman WC, Piller LB, Simpson LM, Levy D, Nwachuku CE, Black HR; ALLHAT Collaborative Research Group.

Am Heart J. 2007 Jan;153(1):42-53.

PMID:
17174636
37.

Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.

Leenen FH, Nwachuku CE, Black HR, Cushman WC, Davis BR, Simpson LM, Alderman MH, Atlas SA, Basile JN, Cuyjet AB, Dart R, Felicetta JV, Grimm RH, Haywood LJ, Jafri SZ, Proschan MA, Thadani U, Whelton PK, Wright JT; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group.

Hypertension. 2006 Sep;48(3):374-84. Epub 2006 Jul 24.

PMID:
16864749
38.

Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Pressel SL, Davis BR, Wright JT, Geraci TS, Kingry C, Ford CE, Piller LB, Bettencourt J, Kimmel B, Lusk C, Parks H, Simpson LM, Nwachuku C, Furberg CD; ALLHAT Collaborative Research Group.

Control Clin Trials. 2001 Feb;22(1):29-41.

PMID:
11165421
39.

Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.

Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, Cuddy TE, Moyé LA, Piller LB, Rutherford J, Simpson LM, Braunwald E.

Circulation. 1999 Jan 19;99(2):216-23.

PMID:
9892586
40.

Entry into, and resuscitation from, the viable but nonculturable state by Vibrio vulnificus in an estuarine environment.

Oliver JD, Hite F, McDougald D, Andon NL, Simpson LM.

Appl Environ Microbiol. 1995 Jul;61(7):2624-30.

41.
42.

Regulation of proteolytic activity of Vibrio vulnificus by iron-containing compounds.

Simpson LM, Oliver JD.

Microb Pathog. 1993 Mar;14(3):249-52.

PMID:
8321126
43.

Reversal of hypotension induced by Vibrio vulnificus lipopolysaccharide in the rat by inhibition of nitric oxide synthase.

Elmore SP, Watts JA, Simpson LM, Oliver JD.

Microb Pathog. 1992 Nov;13(5):391-7.

PMID:
1284317
44.

Use of colistin-polymyxin B-cellobiose agar for isolation of Vibrio vulnificus from the environment.

Oliver JD, Guthrie K, Preyer J, Wright A, Simpson LM, Siebeling R, Morris JG Jr.

Appl Environ Microbiol. 1992 Feb;58(2):737-9.

45.

Physiological effects of the lipopolysaccharide of Vibrio vulnificus on mice and rats.

McPherson VL, Watts JA, Simpson LM, Oliver JD.

Microbios. 1991;67(272-273):141-9.

PMID:
1779875
46.

Phenotypic evaluation of acapsular transposon mutants of Vibrio vulnificus.

Wright AC, Simpson LM, Oliver JD, Morris JG Jr.

Infect Immun. 1990 Jun;58(6):1769-73.

47.

Ability of Vibrio vulnificus to obtain iron from hemoglobin-haptoglobin complexes.

Zakaria-Meehan Z, Massad G, Simpson LM, Travis JC, Oliver JD.

Infect Immun. 1988 Jan;56(1):275-7.

48.

Identification of environmental Vibrio vulnificus isolates with a DNA probe for the cytotoxin-hemolysin gene.

Morris JG Jr, Wright AC, Roberts DM, Wood PK, Simpson LM, Oliver JD.

Appl Environ Microbiol. 1987 Jan;53(1):193-5.

49.

Correlation between virulence and colony morphology in Vibrio vulnificus.

Simpson LM, White VK, Zane SF, Oliver JD.

Infect Immun. 1987 Jan;55(1):269-72.

50.

Bioluminescence in a strain of the human pathogenic bacterium Vibrio vulnificus.

Oliver JD, Roberts DM, White VK, Dry MA, Simpson LM.

Appl Environ Microbiol. 1986 Nov;52(5):1209-11.

Supplemental Content

Loading ...
Support Center